Annual report
4502.TEDINET S100W07G
Period2024-04-01 → 2025-03-31
Filed2025-06-25
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.58T | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥4.26T | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥4.03T | 2022-04-01 → 2023-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥3.57T | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥3.20T | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥342.6bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥214.1bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥175.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥52.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥375.1bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥302.6bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥366.2bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥107.9bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥144.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥317.0bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥230.1bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥376.0bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥108.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥144.2bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥317.0bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥230.2bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥376.2bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Total assets | ¥14.25T | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥15.11T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥13.96T | at 2023-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥13.18T | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥12.91T | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥7.31T | at 2025-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥7.83T | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥6.94T | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥7.27T | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥6.35T | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥6.94T | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥7.27T | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Cash & equivalents | ¥385.1bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥457.8bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥533.5bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥849.7bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥966.2bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥1.06T | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥716.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥977.2bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥1.12T | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥1.01T | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥367.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥463.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥607.1bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥198.1bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | ¥393.5bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥751.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥354.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥709.1bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥1.07T | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥1.09T | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥68.36 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥92.09 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥204.29 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥147.14 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥240.72 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥67.23 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥91.16 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥201.94 | 2022-04-01 → 2023-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥145.87 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥238.96 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥4,407.01 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥4,635.56 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥4,087.49 | at 2023-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥3,665.61 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥3,308.93 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 48.7% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 48.1% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 45.5% | at 2023-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 43.1% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 40.1% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 1.5% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 2.1% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 5.3% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 4.2% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 7.6% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 47,455 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 49,281 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 49,095 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 47,347 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 47,099 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥580.4bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥595.6bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥632.1bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥764.3bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥602.6bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥36.9bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥48.1bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥86.6bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥286.4bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥340.1bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥550.9bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥50.0bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥199.3bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥391.3bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥152.8bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥338.9bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥330.6bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥324.4bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥247.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥9.49T | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥9.76T | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥9.41T | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥9.64T | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥10.86T | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥5.50T | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥5.67T | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥3.99T | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥4.09T | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥4.21T | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥4.29T | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.43T | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥169.6bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥130.9bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥96.79 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥216.6 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥213.06 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥207.5 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥158.45 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥96.78 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥216.56 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥213.05 | 2022-04-01 → 2023-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥207.5 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥158.44 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥196 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥188 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥180 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥180 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥180 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,534.39 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,604.87 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,704.87 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,769.31 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,835.81 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 42.0% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.9% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.7% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.5% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.8% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 3.8% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.4% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.5% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 1,590,950,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,582,419,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,582,296,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,582,253,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,576,388,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 4,808 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 5,474 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 5,486 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 5,149 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 4,966 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 2
| Segment | Item | Period | Value |
|---|---|---|---|
| Pharmaceutical Businessreportable segment | employees | at 2025-03-31 | 47455 pure |
| Pharmaceutical Businessreportable segment | employees | at 2025-03-31 | 4808 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,774
| Item | Context | Value | Unit |
|---|---|---|---|
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00919-000JeanLucButelMember | Original text (Japanese)注６ | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00919-000FujimoriYoshiakiMember | Original text (Japanese)取締役監査等委員 | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00919-000FujimoriYoshiakiMember | Original text (Japanese)藤森義明 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00919-000FujimoriYoshiakiMember | 1951-07-03 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E00919-000FujimoriYoshiakiMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00919-000FujimoriYoshiakiMember | Original text (Japanese)注６ | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00919-000KimberlyReedMember | Original text (Japanese)取締役監査等委員 | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00919-000KimberlyReedMember | Original text (Japanese)キンバリーリード(KimberlyReed) | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00919-000KimberlyReedMember | 1971-03-11 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E00919-000KimberlyReedMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00919-000KimberlyReedMember | Original text (Japanese)注６ | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row3Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row4Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row5Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row6Member | Text · Plus | |
| Outside directors and outside corporate auditors (text) | FilingDateInstant | Text · Plus | |
| Audits (text) | FilingDateInstant | Text · Plus | |
| Remuneration for directors and other officers (text) | FilingDateInstant | Text · Plus | |
| Remuneration etc paid by group to each director or other officer (text) | FilingDateInstant | Text · Plus | |
| Shareholdings (text) | FilingDateInstant | Text · Plus | |
| Reason for increase in number of shares shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | Original text (Japanese)新規投資、転換社債権利行使、および持分法適用関連会社からの区分変更 | |
| Reason for increase in number of shares shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | Original text (Japanese)上場に伴う区分変更 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)あすか製薬ホールディングス株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)有（注３） | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)Chordia Therapeutics 株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)ノイルイミューン・バイオテック株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Ovid Therapeutics, Inc. | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Denali Therapeutics, Inc. | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Phathom Pharmaceuticals, Inc. | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Wave LifeSciences, Ltd. | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)無 | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row1Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row2Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row3Member | Text · Plus | |
| Description of fact that consolidated financial statements have been prepared in accordance with IFRS financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |